Desolvation process and surface characterisation of protein nanoparticles

Weber, Carolin; Coester, Conrad; Kreuter, Jörg; Langer, Klaus

doi:10.1016/s0378-5173(99)00370-1

Cited by 531 publications

(406 citation statements)

References 21 publications

Supporting

Mentioning

376

Contrasting

Unclassified

Order By: Relevance

“…Albumin nanoparticles were prepared by the disolvationcrosslinking technique. 31 BSANPs with smooth surfaces, good dispersion and relatively uniform size distributions were obtained. The mean diameters of BSANPs were 130 nm.…”

Section: Discussionmentioning

confidence: 97%

RGD-conjugated albumin nanoparticles as a novel delivery vehicle in pancreatic cancer therapy

Zhang

et al. 2012

Cancer Biology & Therapy

View full text Add to dashboard Cite

These authors contributed equally to this work. Keywords: nanoparticles, albumin, RGD, FITC, delivery, pancreatic cancer, therapyIntegrin avb3 receptor is expressed on several types of cancer cells, including pancreatic cancer cells, and plays an important role in tumor growth and metastasis. The ability to target the integrin avb3 receptor on cancer cells increases the efficacy of targeted therapy and reduces the side effects. The aim of this study is to develop a novel arginine-glycineaspartic acid (RGD) peptide-conjugated albumin nanoparticle to enhance the intracellular uptake of anticancer drug into the pancreatic cancer cells through receptor-mediated endocytosis. In cellular uptake studies, the fluorescent signal of RGD-conjugated BSANPs in BxPC3 cells was higher than that of BSANPs without RGD conjugation as determined by fluorescence spectrophotometer. We also found that BSANPs bound to BxPC3 cells in a time-and concentration-dependent manner. The uptake of RGD-conjugated BSANPs by pancreatic cancer cells was inhibited by an excess amount of free RGD peptide, indicating that the binding and/or uptake were mediated by the avb3 receptor. Furthermore, the nanoparticles were found to be located close to the nuclei by using laser scanning confocal microscopy. Besides, no significant in vitro cytotoxicity was observed as measured with MTT assay. Both in vitro and in vivo antitumor efficacy was improved by targeting gemcitabine-loaded nanoparticles to BxPC-3 cells using RGD peptides. Therefore, the RGD-conjugated BSANPs hold great potential as an effective drug delivery system to deliver therapeutic agents to pancreatic cancer.

show abstract

Section: Discussionmentioning

confidence: 97%

RGD-conjugated albumin nanoparticles as a novel delivery vehicle in pancreatic cancer therapy

Zhang

et al. 2012

Cancer Biology & Therapy

View full text Add to dashboard Cite

show abstract

“…Their subcellular size provides several advantages such as prolonged gastrointestinal residence, better tissue penetration, and superior cellular uptake [4]. Besides, these nanoparticles exhibit lower cytotoxicity and higher degradability [5]. All of these features make them an attractive candidate as an efficacy enhancer for the functional foods.…”

Section: Introductionmentioning

confidence: 99%

Preparation, Characterization and In vitro Evaluation of Theophylline Nanoparticles Prepared with Dextran- Conjugated Soy Protein

Jin¹,

Zhou²,

Chen³

et al. 2015

Trop. J. Pharm Res

View full text Add to dashboard Cite

“…In the present study, doxorubicin was incorporated into the matrix of human serum albumin, and three different particle-sized fractions of doxorubicin-loaded HSA nanoparticles were prepared using a previously described desolvation method [16,17]. HSA nanoparticles offer several specific advantages [16]: these colloid compounds are biodegradable and well-tolerated, preparation is easy and reproducible [17], and it is possible to bind targeting ligands to particles by covalent bonding, due to the presence of functional groups [18][19][20][21].…”

Section: Introductionmentioning

confidence: 99%

“…HSA nanoparticles offer several specific advantages [16]: these colloid compounds are biodegradable and well-tolerated, preparation is easy and reproducible [17], and it is possible to bind targeting ligands to particles by covalent bonding, due to the presence of functional groups [18][19][20][21].…”

Section: Introductionmentioning

confidence: 99%

In vitro and biodistribution examinations of Tc-99m-labelled doxorubicin-loaded nanoparticles

Polyák¹,

Palade²,

Pöstényi³

et al. 2011

Nucl Med Rev Cent East Eur.

View full text Add to dashboard Cite

BACKGROUND: Nanoparticles represent promising drug carrier systems. In the case of cytostatics such as doxorubicin, carrier colloid systems as human serum albumin (HSA) nanoparticles, may increase their therapeutic efficiency and decrease their side-effects (toxicity) and any potential multidrug resistance. In the present study, doxorubicin, as a widely used antineoplastic agent, was incorporated into the matrix of human serum albumin and three different particle-sized doxorubicin-loaded HSA nanoparticles were prepared, using a previously described desolvation method. Our objective was to find out if different particle sizes of colloid carriers can allow regarding the given cytostatic agent. MATERIAL AND METHODS:The three prepared nanoparticles were labelled using technetium (Tc-99m) and were tested for their physicochemical colloidal quality, fluctuations, and radio- RESULTS:In vitro measurements showed that more than 95% of doxorubicin proportion was permanently adsorbed to human serum albumin. Radiolabelled doxorubicin-loaded particles had high-degree and durable labelling efficiency and particle size stability. Biodistribution results had a close correlation to earlier described results of radiocolloids in similar particle size ranges.In vivo examinations verified that colloid carriers have insignificant size fluctuations after an intravenous application and they show the proper distribution according to their particle size. CONCLUSIONS: Our investigations verified that different and stable particle sizes make drug carrier HSA nanoparticles possible to apply different drug targeting in a potential clinical use.

show abstract

Desolvation process and surface characterisation of protein nanoparticles

Cited by 531 publications

References 21 publications

RGD-conjugated albumin nanoparticles as a novel delivery vehicle in pancreatic cancer therapy

RGD-conjugated albumin nanoparticles as a novel delivery vehicle in pancreatic cancer therapy

Preparation, Characterization and In vitro Evaluation of Theophylline Nanoparticles Prepared with Dextran- Conjugated Soy Protein

In vitro and biodistribution examinations of Tc-99m-labelled doxorubicin-loaded nanoparticles

Contact Info

Product

Resources

About